title: [Reduction of pain and muscle spasms by botulinum toxin A].
abstract: Botulinum toxin A (BoNT-A) develops its muscle-relaxing effect by the inhibition of acetylcholine (ACh) release. This toxin is also known to relieve muscular pain in different disorders. Conspicuously, pain in some patients responds earlier and sometimes even better than muscle tension, indicating that the effect of BoNT-A on pain is not only due to inhibition of ACh release. A questionnaire was distributed to 88 patients suffering from cervical dystonia (CD). Thirty-five completed questionnaires could be used for data analysis. After intramuscular injections of BoNT-A, patients with CD experience significant reductions in pain which sometimes occur significantly earlier than the improvements in head posture. In the iris sphincter muscle of the rabbit and in dorsal root ganglion cells (DRG) of the rat, inhibition of the release of substance P by BoNT-A has been shown experimentally, and BoNT-C has been proven to develop endopeptidase activity toward substance P (SP) in vitro. Findings in the current literature and our observations allow the conclusion that alleviation of muscle pain by BoNT-A may also be due to an effect on the release of nociceptive neuropeptides, among which SP seems to have a key function.
authors.affiliation: Neurologische Klinik der Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225 Düsseldorf. Stefan.Kelm@uni-duesseldorf.de
authors.forename: S
authors.initials: S
authors.lastname: Kelm
authors.forename: G
authors.initials: G
authors.lastname: Gerats
authors.forename: A
authors.initials: A
authors.lastname: Chalkiadaki
authors.forename: H
authors.initials: H
authors.lastname: Hefter
mesh_terms: D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002908:Chronic Disease; D020821:Dystonic Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D010147:Pain Measurement; D017060:Patient Satisfaction; D012494:Sampling Studies; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D018712:Analgesics, Non-Narcotic; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A